Removal from liver transplantation list of a hepatitis C virus‐HIV co‐infected patient after successful treatment with sofosbuvir and daclatasvir

We present a human immunodeficiency virus‐infected patient with severe decompensated hepatitis C virus‐related cirrhosis awaiting liver transplantation (LT) who received a 24‐week course of interferon/ribavirin‐free antiviral treatment with sofosbuvir and daclatasvir on a compassionate basis. Rapid...

Full description

Saved in:
Bibliographic Details
Published inTransplant infectious disease Vol. 18; no. 3; pp. 442 - 445
Main Authors Llaneras, J., Castells, L., Santos, B., Crespo, M., Puig, T., Esteban, J.I., Esteban, R.
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.06.2016
Subjects
Antiretroviral drugs
daclatasvir
Hepatitis
hepatitis C virus
HIV
Human immunodeficiency virus
Liver
sofosbuvir
transplant
sofosbuvir
hepatitis C virus
human immunodeficiency virus
transplant
daclatasvir
Online AccessGet full text

Cover

More Information
Summary:We present a human immunodeficiency virus‐infected patient with severe decompensated hepatitis C virus‐related cirrhosis awaiting liver transplantation (LT) who received a 24‐week course of interferon/ribavirin‐free antiviral treatment with sofosbuvir and daclatasvir on a compassionate basis. Rapid viral suppression was associated with progressive improvement of his liver function tests. The patient achieved a sustained virological response and concomitant clinical improvement, which prompted removal from the LT list 12 weeks after the end of treatment.
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.12538